Despite recent progress, Incyte still far off from pricing goal for key eczema launch Opzelura

After an approval last fall, Incyte has been offering big discounts on its newly launched atopic dermatitis cream Opzelura to stimulate patient access. Although still far from an ambitious year-end pricing goal, the company believes improvements in reimbursement deals will lift the average price it can charge for the new treatment.